U.S. markets close in 3 hours 30 minutes

Roche Holding AG (RO.SW)

Swiss - Swiss Delayed Price. Currency in CHF
Add to watchlist
386.40+4.40 (+1.15%)
At close: 05:30PM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close382.00
Bid380.00 x 0
Ask387.20 x 0
Day's Range381.80 - 387.60
52 Week Range299.40 - 427.80
Avg. Volume38,547
Market Cap314.391B
Beta (5Y Monthly)0.28
PE Ratio (TTM)23.79
EPS (TTM)16.24
Earnings DateJul 23, 2020
Forward Dividend & Yield9.10 (2.38%)
Ex-Dividend DateMar 18, 2021
1y Target Est397.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for RO.SW

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Zacks

      ImmunoGen (IMGN) Surges on Successful Ovarian Cancer Study

      ImmunoGen (IMGN) reports successful completion of a pivotal study evaluating its lead pipeline candidate as monotherapy in certain ovarian cancer patients previously treated with Avastin.

    • GlobeNewswire

      Roche completes purchase agreement with long-term partner TIB Molbiol to expand PCR-test portfolio in the fight against new infectious diseases

      TIB Molbiol excels in ultra-rapid assay development for emerging infectious disease, strongly demonstrated during the COVID-19 pandemicThe acquisition enables Roche to further expand the portfolio of currently over 45 CE-IVD assays and more than 100 research use assays on Roche’s LightCycler PCR instrumentsTIB Molbiol will continue to focus on the research and development of assays that rapidly address critical healthcare needs including biological threats Basel, 1 December 2021 - Roche (SIX: RO

    • Zacks Small Cap Research

      SQZ: Something New to Squeeze Into Your Portfolio

      By John Vandermosten, CFA NYSE:SQZ READ THE FULL SQZ RESEARCH REPORT We are initiating coverage of SQZ Biotechnologies Company (NYSE:SQZ) with a current valuation of $30.00 per share. This present value is based on our estimates for a successful development of the Antigen Presenting Cell (APC), Activating Antigen Carrier (AAC) and Tolerizing Antigen Carrier (TAC) platforms in HPV positive solid